Corrigendum to “FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling” [Cancer Lett. 402 (2017) 166–176] (Cancer Letters (2017) 402 (166–176), (S0304383517303750), (10.1016/j.canlet.2017.05.029));FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling

Cancer Letters

Volumn 402, Issue , 2017, Pages 166-176

  Li, Qiji ^a   Ye, Liping ^b   Xin, Zhang ^b   Wang, Min ^a   Lin, Chuyong ^b   Huang, Shuai ^a   Guo, Wei ^a   Lai, Yingrong ^a   Du, Hong ^c   Li, Jun ^d   Song, Libing ^b   Peng, Xinsheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bone metastasis; Canonical Wnt catenin; FZD8; p53; Prostate cancer

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; PROTEIN FZD8; UNCLASSIFIED DRUG; WNT PROTEIN; CELL SURFACE RECEPTOR; FZD8 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN P53; TP53 PROTEIN, HUMAN;

AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR INVASION; WILD TYPE; WNT SIGNALING PATHWAY; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BONE TUMOR; CELL MOTION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; SECONDARY; TIME FACTOR; TUMOR CELL LINE; WNT SIGNALING;

AGED; ANIMALS; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 85020775090     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.07.050     Document Type: Erratum

References (58)

1. Langley, R.R., Fidler, I.J., The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128 (2011), 2527–2535.
2. Coleman, R.E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27 (2001), 165–176.
3. Saad, F., Lipton, A., Cook, R., Chen, Y.M., Smith, M., Coleman, R., Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110 (2007), 1860–1867.
4. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics (2012). CA Cancer J. Clin. 65 (2015), 87–108.
5. Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66 (2016), 115–132.
6. Weinfurt, K.P., The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16 (2005), 579–584.
7. Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31 (2000), 578–583.
8. Giles, R.H., van Es, J.H., Clevers, H., Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653 (2003), 1–24.
9. Nguyen, D.X., Chiang, A.C., Zhang, X.H., Kim, J.Y., Kris, M.G., Ladanyi, M., et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138 (2009), 51–62.
10. Bendinelli, P., Maroni, P., Matteucci, E., Luzzati, A., Perrucchini, G., Desiderio, M.A., Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. Biochim. Biophys. Acta 1843 (2014), 815–826.
11. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349 (2003), 2483–2494.
12. Rabbani, S.A., Arakelian, A., Farookhi, R., LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2 (2013), 625–635.
13. Dai, J., Hall, C.L., Escara-Wilke, J., Mizokami, A., Keller, J.M., Keller, E.T., Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 68 (2008), 5785–5794.
14. Chen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004), 1345–1356.
15. Francis, J.C., Thomsen, M.K., Taketo, M.M., Swain, A., beta-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet., 9, 2013, e1003180.
16. Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
17. Nandana, S., Tripathi, M., Duan, P., Chu, C.Y., Mishra, R., Liu, C., et al. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res. 77 (2017), 1331–1344.
18. Kim, T.H., Xiong, H., Zhang, Z., Ren, B., beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 24 (2005), 597–604.
19. Yang, X.H., Li, L., Huang, Q., Xu, W., Cai, X.P., Zhang, J.S., et al. Wnt signaling through Snail1 and Zeb1 regulates bone metastasis in lung cancer. Am. J. Cancer Res. 5 (2015), 748–755.
20. Dong, Y.F., Soung do, Y., Schwarz, E.M., O'Keefe, R.J., Drissi, H., Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J. Cell Physiol. 208 (2006), 77–86.
21. Li, X.Q., Du, X., Li, D.M., Kong, P.Z., Sun, Y., Liu, P.F., et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFbeta signaling pathway. Cancer Res. 75 (2015), 3302–3313.
22. Rucci, N., Millimaggi, D., Mari, M., Del Fattore, A., Bologna, M., Teti, A., et al. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res. 70 (2010), 6150–6160.
23. Zhang, X., Gaspard, J.P., Chung, D.C., Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61 (2001), 6050–6054.
24. Aumiller, V., Balsara, N., Wilhelm, J., Gunther, A., Konigshoff, M., WNT/beta-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 49 (2013), 96–104.
25. Zheng, Y., Basel, D., Chow, S.O., Fong-Yee, C., Kim, S., Buttgereit, F., et al. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin. Exp. Metastasis 31 (2014), 921–933.
26. Moses, M.A., Wiederschain, D., Loughlin, K.R., Zurakowski, D., Lamb, C.C., Freeman, M.R., Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58 (1998), 1395–1399.
27. Wu, B., Crampton, S.P., Hughes, C.C., Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26 (2007), 227–239.
28. Ueno, K., Hirata, H., Hinoda, Y., Dahiya, R., Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int. J. Cancer 132 (2013), 1731–1740.
29. Wissmann, C., Wild, P.J., Kaiser, S., Roepcke, S., Stoehr, R., Woenckhaus, M., et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201 (2003), 204–212.
30. Formosa, A., Markert, E.K., Lena, A.M., Italiano, D., Finazzi-Agro, E., Levine, A.J., et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33 (2014), 5173–5182.
31. Ren, W., Li, C., Duan, W., Du, S., Yang, F., Zhou, J., et al. MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7. Biochem. Biophys. Res. Commun. 469 (2016), 633–638.
32. Li, X., Liang, W., Liu, J., Lin, C., Wu, S., Song, L., et al. Transducin (beta)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling. Breast Cancer Res., 16, 2014, 465.
33. Lin, C., Song, L., Liu, A., Gong, H., Lin, X., Wu, J., et al. Overexpression of AKIP1 promotes angiogenesis and lymphangiogenesis in human esophageal squamous cell carcinoma. Oncogene 34 (2015), 384–393.
34. Wang, H.Q., Xu, M.L., Ma, J., Zhang, Y., Xie, C.H., Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem. Biophys. Res. Commun. 417 (2012), 62–66.
35. Puca, R., Nardinocchi, L., Gal, H., Rechavi, G., Amariglio, N., Domany, E., et al. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 68 (2008), 3707–3714.
36. Dieter, S.M., Ball, C.R., Hoffmann, C.M., Nowrouzi, A., Herbst, F., Zavidij, O., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9 (2011), 357–365.
37. Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31 (2013), 539–544.
38. Ricci, E., Mattei, E., Dumontet, C., Eaton, C.L., Hamdy, F., van der Pluije, G., et al. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate 73 (2013), 1738–1746.
39. Colombel, M., Eaton, C.L., Hamdy, F., Ricci, E., van der Pluijm, G., Cecchini, M., et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 72 (2012), 713–720.
40. Hurt, E.M., Kawasaki, B.T., Klarmann, G.J., Thomas, S.B., Farrar, W.L., CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 98 (2008), 756–765.
41. Sheng, X., Li, Z., Wang, D.L., Li, W.B., Luo, Z., Chen, K.H., et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol. Lett. 5 (2013), 787–792.
42. Ma, F., Ye, H., He, H.H., Gerrin, S.J., Chen, S., Tanenbaum, B.A., et al. SOX9 drives WNT pathway activation in prostate cancer. J. Clin. Investig. 126 (2016), 1745–1758.
43. Wang, M.T., Holderfield, M., Galeas, J., Delrosario, R., To, M.D., Balmain, A., et al. K-ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163 (2015), 1237–1251.
44. Sun, S., Liu, S., Duan, S.Z., Zhang, L., Zhou, H., Hu, Y., et al. Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res. 74 (2014), 7546–7559.
45. Yamada, N., Noguchi, S., Mori, T., Naoe, T., Maruo, K., Akao, Y., Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett. 335 (2013), 332–342.
46. Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461 (2009), 614–620.
47. Deb, A., Davis, B.H., Guo, J., Ni, A., Huang, J., Zhang, Z., et al. SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a. Stem Cells 26 (2008), 35–44.
48. Wong, J., Li, P.X., Klamut, H.J., A novel p53 transcriptional repressor element (p53TRE) and the asymmetrical contribution of two p53 binding sites modulate the response of the placental transforming growth factor-beta promoter to p53. J. Biol. Chem. 277 (2002), 26699–26707.
49. Gupta, S., Iljin, K., Sara, H., Mpindi, J.P., Mirtti, T., Vainio, P., et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 70 (2010), 6735–6745.
50. Yin, S., Xu, L., Bonfil, R.D., Banerjee, S., Sarkar, F.H., Sethi, S., et al. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther. 12 (2013), 491–498.
51. Dijksterhuis, J.P., Petersen, J., Schulte, G., WNT_Frizzled signalling_ receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance_ IUPHAR Review 3. Br. J. Pharmacol. 171 (2014), 1195–1209.
52. Bisson, I., Prowse, D.M., WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19 (2009), 683–697.
53. Powell, E., Piwnica-Worms, D., Piwnica-Worms, H., Contribution of p53 to metastasis. Cancer Discov. 4 (2014), 405–414.
54. Rother, K., Johne, C., Spiesbach, K., Haugwitz, U., Tschop, K., Wasner, M., et al. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 23 (2004), 3376–3384.
55. Levina, E., Oren, M., Ben-Ze'ev, A., Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 23 (2004), 4444–4453.
56. Sadot, E., Geiger, B., Oren, M., Ben-Ze'ev, A., Down-regulation of beta-catenin by activated p53. Mol. Cell Biol. 21 (2001), 6768–6781.
57. Prowald, A., Cronauer, M.V., von Klot, C., Eilers, T., Rinnab, L., Herrmann, T., et al. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. Prostate 67 (2007), 1751–1760.
58. Cha, Y.H., Kim, N.H., Park, C., Lee, I., Kim, H.S., Yook, J.I., MiRNA-34 intrinsically links p53tumor suppressor and Wnt signaling. Cell Cycle 11 (2012), 1273–1281.